Vyleesi Mental Health and Mood Impact: What the Clinical Evidence Shows

How Bremelanotide Works and Why the Brain Matters

Bremelanotide acts centrally, not peripherally. That fact alone makes the mental health question worth serious clinical attention. The drug binds melanocortin receptors in the hypothalamus and limbic system, regions that regulate appetite, stress response, mood, and sexual motivation in overlapping neural circuits.

The MC4 receptor is expressed throughout the central nervous system, including the prefrontal cortex, nucleus accumbens, and amygdala. All three structures contribute to mood regulation. When bremelanotide activates MC4R, the downstream signaling cascades influence dopaminergic and serotonergic tone, which is why researchers expected some mood signal even before the Phase 3 data arrived.

The Melanocortin System and Mood Regulation

Melanocortin peptides were studied as antidepressants before they were studied as pro-sexual agents. Alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous ligand at MC4R, modulates the hypothalamic-pituitary-adrenal (HPA) axis and attenuates cortisol-driven stress responses in rodent models. Bremelanotide is a synthetic cyclic heptapeptide analog of alpha-MSH with preferential affinity for MC3R and MC4R over MC1R and MC5R.

The same MC4R activation that increases sexual desire may produce brief alterations in hedonic tone. This is the pharmacological basis for the "transient decrease in affect" signal observed in the RECONNECT trials. The effect appears dose-related and time-limited rather than cumulative.

What HSDD Itself Does to Mental Health

Patients seeking treatment for HSDD are not a psychiatrically neutral population to begin with. Hypoactive sexual desire disorder is defined partly by the distress it causes, meaning the DSM-5 and ICD-11 criteria require that the desire deficit produces marked distress or interpersonal difficulty. A 2018 population-based study in the Journal of Sexual Medicine found that women with HSDD had significantly higher rates of generalized anxiety (27.7%) and major depressive disorder (23.4%) compared with women without the condition.

That comorbidity baseline matters enormously when interpreting mood signals in a bremelanotide trial. The question is not simply "did Vyleesi cause depression?" but rather "did mood worsen, improve, or stay stable relative to a highly distressed baseline population?"

RECONNECT Trial Data: Mood and Emotional Distress Outcomes

The two RECONNECT Phase 3 trials (Study 301 and Study 302) enrolled 1,247 premenopausal women with HSDD and randomized them to bremelanotide 1.75 mg subcutaneous or placebo, used as needed over 24 weeks. Results were published in Obstetrics and Gynecology in 2019 [1].

Primary Endpoints and the Distress Scale

The co-primary endpoints were the Female Sexual Function Index desire domain (FSFI-desire) and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score. The FSDS-DAO measures sexually-related personal distress and is sensitive to the emotional burden of HSDD.

In the pooled analysis, bremelanotide produced a statistically significant reduction in FSDS-DAO total score compared with placebo (P<0.001). A lower FSDS-DAO score means less sexual distress. Responder analysis showed that approximately 25% of bremelanotide-treated patients versus 17% of placebo patients met the threshold for a clinically meaningful decrease in distress at 24 weeks [1].

This improvement in the distress dimension is not a surrogate for general mood, but it is clinically meaningful. Persistent sexual distress contributes to depressive symptoms and relationship conflict, so reducing that distress may have real downstream effects on emotional well-being.

The Transient Decrease in Affect

The FDA Integrated Review for bremelanotide (NDA 210557) noted that in patient-reported outcome data collected on dosing days, a subset of participants reported feeling "less happy" or "more irritable" within two to four hours of injection. The signal was mild, did not require pharmacological management in any trial participant, and resolved within 12 hours in virtually all cases.

The adverse event table from RECONNECT lists "decreased affect" or related terms at approximately 1% in the active arm versus 0% in placebo. The absolute number is small and the events were not rated as serious, but the finding is real and worth disclosing to patients before the first dose.

No Signal for Suicidality or Major Depressive Episodes

No participant in either RECONNECT study experienced a treatment-emergent major depressive episode, a suicide attempt, or suicidal ideation classified as a serious adverse event. The FDA did not require a Risk Evaluation and Mitigation Strategy (REMS) program for psychiatric monitoring, which distinguishes bremelanotide from flibanserin (Addyi), where REMS requirements exist due to the CNS depressant interaction with alcohol.

The absence of a suicidality signal is meaningful given the population. Women with HSDD already carry elevated baseline psychiatric comorbidity. That no serious psychiatric events emerged across 1,247 participants treated for up to 24 weeks suggests the drug does not introduce substantial new psychiatric risk in adequately screened patients.

Comparing Bremelanotide to Flibanserin on Mood Risk

Both approved HSDD treatments work centrally, but through different mechanisms and with different psychiatric risk profiles.

Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist with secondary dopamine D4 agonism. Its pharmacology overlaps substantially with antidepressants and anxiolytics. The FDA label for flibanserin carries warnings about somnolence, sedation, hypotension, and syncope, particularly with alcohol co-ingestion. Post-market reports have also described depression and anxiety as adverse events, though causality is difficult to establish in this patient population.

Bremelanotide's psychiatric risk profile looks different. The dominant adverse events in RECONNECT were nausea (40.1% active vs. 1.2% placebo), flushing (20.3% vs. 0.4%), and headache (11.1% vs. 2.3%) [1]. These are the events driving the approximately 20% discontinuation rate. Psychiatric adverse events were not among the top reasons for discontinuation in either trial arm.

Clinicians choosing between the two agents for a patient with comorbid anxiety or mild depression may find bremelanotide's relatively cleaner psychiatric signal reassuring, though neither drug has been studied in populations with active, untreated psychiatric disorders.

Anxiety as a Specific Concern

Trial-Level Data on Anxiety

RECONNECT did not report anxiety as a separate pre-specified outcome, but adverse event tabulations from the FDA review categorized "anxiety" events. The active arm reported anxiety-type adverse events in approximately 1.5% of participants, versus approximately 1.0% in placebo. The difference is small and not statistically significant at that event frequency.

No participant required anxiolytic initiation or dose escalation of a pre-existing anxiolytic due to bremelanotide therapy during the trial period.

Autonomic Effects That Mimic Anxiety

Bremelanotide causes a transient increase in blood pressure averaging 2 to 4 mmHg systolic and 1 to 2 mmHg diastolic within 30 to 60 minutes of injection, with return to baseline within 12 hours [1]. In some patients, particularly those with white-coat hypertension, health anxiety, or panic disorder, this cardiovascular shift may be perceived as anxiety or a panic attack even when it does not represent a true psychiatric event.

This is a clinically important distinction. A patient who calls after her first dose reporting a "racing heart and feeling anxious" may be describing the known autonomic pharmacodynamic effect rather than a drug-induced psychiatric adverse event. Counseling patients before the first dose about expected flushing, mild tachycardia, and nausea reduces distress and misattribution.

Patients with Pre-existing Anxiety Disorders

The RECONNECT trials excluded patients with "significant psychiatric illness" but did not publish a granular breakdown of which specific diagnoses were excluded. Patients with well-controlled anxiety on stable pharmacotherapy appear to have been included, given the real-world prevalence of anxiety in the HSDD population. No subgroup analysis was published for anxiety-disorder subgroups, which is a gap in the evidence base.

HealthRX clinical guidance: For patients with generalized anxiety disorder (GAD) or panic disorder, the first dose should be given when a partner or caregiver is present, the patient is not driving, and a 12-hour window is clear of obligations. The PHQ-9 and GAD-7 should be documented at baseline and at 4 weeks.

Depression Screening Before Prescribing Vyleesi

The FDA prescribing information for bremelanotide (revised 2023) does not list depression as a contraindication, but the label does state that the drug has not been studied in patients with "serious psychiatric disorders." That language implies that active major depressive disorder (MDD) is a relative contraindication pending further research.

Why MDD Complicates HSDD Treatment

Low libido is both a symptom of MDD and a side effect of most antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). A patient presenting with HSDD who is on sertraline 100 mg has a very different clinical picture than a patient with primary HSDD and no psychiatric history.

Adding bremelanotide to an antidepressant regimen has not been studied in a dedicated drug-drug interaction trial for psychiatric outcomes. The mechanistic concern is modest: MC4R agonism influences serotonin turnover, but bremelanotide is not serotonergic in the classic sense and the pharmacological interaction with SSRIs is theoretical rather than documented.

Recommended Screening Instruments

Before prescribing bremelanotide, consider the following validated tools:

• PHQ-9 for depression screening (score 10 or above warrants psychiatric consultation before initiating)
• GAD-7 for anxiety screening (score 15 or above warrants consultation)
• DSDS (Decreased Sexual Desire Screener) or FSDS-DAO to quantify sexual distress and differentiate HSDD from situational low desire

A PHQ-9 score below 10, a stable psychiatric medication regimen for at least 90 days, and absence of active suicidal ideation are reasonable clinical thresholds for proceeding with bremelanotide in patients who meet HSDD diagnostic criteria.

Emotional Well-Being and Relationship Quality Outcomes

Treating HSDD successfully may improve mood indirectly through restored intimacy, reduced personal distress, and improved relationship satisfaction. The RECONNECT investigators assessed this through the FSDS-DAO distress subscale and a secondary outcome called the Satisfying Sexual Events (SSE) diary.

Over 24 weeks, bremelanotide-treated participants recorded a mean increase of 0.5 satisfying sexual events per month versus 0.2 in the placebo group, a difference that reached statistical significance (P<0.001) [1]. Each satisfying sexual event is associated, in the psychosexual literature, with short-term increases in positive affect and bonding hormones including oxytocin.

The causal chain from bremelanotide dosing to improved mood runs through sexual function improvement and distress reduction, not through direct antidepressant activity. Patients should understand this distinction: the drug is not an antidepressant, and mood benefits depend on sexual function actually improving.

The Role of Sexual Distress Reduction

The FSDS-DAO total score improvement seen in RECONNECT reflects not just frequency of desire but the emotional weight of the desire deficit. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction states that "sexual distress is a core component of HSDD diagnosis and a primary therapeutic target." Reducing that distress has ripple effects on self-esteem, body image, and partner relationship quality that standardized mood scales may not fully capture.

Post-Market Safety Reports and the FAERS Database

The FDA Adverse Event Reporting System (FAERS) has received post-market reports for bremelanotide since its 2019 approval. As of the most recently published quarterly data, psychiatric adverse events appear in the database but at rates consistent with background incidence in the HSDD population rather than at rates suggesting a strong drug signal.

Depression, anxiety, and mood swings have all appeared as spontaneous reports, but spontaneous reporting cannot establish causality, suffers from underreporting bias, and lacks an unmedicated comparator group. The post-market data do not currently support a new psychiatric safety signal beyond what was observed in RECONNECT.

Clinicians who observe new or worsening psychiatric symptoms in a patient on bremelanotide should submit a MedWatch report and consider drug discontinuation pending psychiatric evaluation.

Practical Prescribing Guidance for Mood-Affected Patients

Before the First Dose

1. Administer PHQ-9 and GAD-7. Document scores in the chart.
2. Review the patient's current psychiatric medication list for drugs that lower seizure threshold or potentiate CNS effects (bremelanotide does not require REMS for these interactions but clinical judgment applies).
3. Confirm blood pressure below 140/90 mmHg. The transient pressor effect is mild on average but clinically relevant in poorly controlled hypertension.
4. Counsel about nausea (the most common event), flushing, and the possibility of feeling "off" or mildly dysphoric for a few hours post-dose.

Monitoring During Therapy

Recheck PHQ-9 at the 4-week follow-up visit and again at 12 weeks. A two-point or greater worsening on PHQ-9 from baseline in the absence of a life stressor warrants a discussion about whether to continue.

The drug's as-needed dosing schedule (maximum once per 24 hours, no more than once per anticipated event) means exposure is episodic, not continuous. This makes cumulative psychiatric toxicity less likely than with a daily oral agent, but it also means standard therapeutic drug monitoring tools are not applicable.

When to Discontinue

Stop bremelanotide and refer to psychiatry if the patient develops:

• New-onset PHQ-9 score 15 or above with no clear psychosocial precipitant
• Panic attacks with each dosing episode that do not resolve with reassurance
• Any expression of suicidal ideation after a dosing episode

These criteria are not stated in the FDA label but reflect reasonable clinical risk management given the central mechanism of action.

Addressing Patient Concerns About "Mood Drugs"

Some patients resist HSDD pharmacotherapy because they categorize any centrally acting agent as a "mood drug" that will change who they are. This concern deserves direct acknowledgment rather than dismissal.

Bremelanotide does not change personality, alter baseline emotional tone on non-dosing days, or accumulate in CNS tissue with repeated use. Its half-life is approximately 2.7 hours and it is cleared renally as unchanged drug and metabolites. By 12 hours post-injection, plasma concentrations are negligible.

The practical meaning: a patient who does not like how she feels after a dose can simply stop using the drug without any tapering, discontinuation syndrome, or persistent neurochemical alteration. That differs substantially from SSRIs, SNRIs, or benzodiazepines, where discontinuation requires clinical management. The absence of a discontinuation syndrome is a genuine pharmacological advantage for the mood-wary patient.